Cargando…
S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428456/ http://dx.doi.org/10.1097/01.HS9.0000967908.22295.e4 |
| _version_ | 1785090473713467392 |
|---|---|
| author | Van Dijck, Ruben VAN DER Holt, Ron Meijer, Ellen Devos, Timothy Hazenberg, Mette Van Der Poel, Marjolein Breems, Dimitri Deleu, Lien Schaap, Nicolaas Te Boekhorst, Peter André Willem |
| author_facet | Van Dijck, Ruben VAN DER Holt, Ron Meijer, Ellen Devos, Timothy Hazenberg, Mette Van Der Poel, Marjolein Breems, Dimitri Deleu, Lien Schaap, Nicolaas Te Boekhorst, Peter André Willem |
| author_sort | Van Dijck, Ruben |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428456 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104284562023-08-17 S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL Van Dijck, Ruben VAN DER Holt, Ron Meijer, Ellen Devos, Timothy Hazenberg, Mette Van Der Poel, Marjolein Breems, Dimitri Deleu, Lien Schaap, Nicolaas Te Boekhorst, Peter André Willem Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428456/ http://dx.doi.org/10.1097/01.HS9.0000967908.22295.e4 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Van Dijck, Ruben VAN DER Holt, Ron Meijer, Ellen Devos, Timothy Hazenberg, Mette Van Der Poel, Marjolein Breems, Dimitri Deleu, Lien Schaap, Nicolaas Te Boekhorst, Peter André Willem S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL |
| title | S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL |
| title_full | S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL |
| title_fullStr | S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL |
| title_full_unstemmed | S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL |
| title_short | S249: SELECTIVE JAK2/IRAK1/ACVR1 INHIBITOR PACRITINIB BEFORE REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELOFIBROSIS: FINAL ANALYSIS OF THE PHASE II HOVON-134 TRIAL |
| title_sort | s249: selective jak2/irak1/acvr1 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation in myelofibrosis: final analysis of the phase ii hovon-134 trial |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428456/ http://dx.doi.org/10.1097/01.HS9.0000967908.22295.e4 |
| work_keys_str_mv | AT vandijckruben s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT vanderholtron s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT meijerellen s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT devostimothy s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT hazenbergmette s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT vanderpoelmarjolein s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT breemsdimitri s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT deleulien s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT schaapnicolaas s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial AT teboekhorstpeterandrewillem s249selectivejak2irak1acvr1inhibitorpacritinibbeforereducedintensityconditioningallogeneicstemcelltransplantationinmyelofibrosisfinalanalysisofthephaseiihovon134trial |